Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

NCT07494435 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepato Cellular Carcinoma (HCC)
Renal Cell Cancer

Interventions

DRUG: WGI-0301
DRUG: Nivolumab (240 mg)
DRUG: WGI-0301

Sponsor

Zhejiang Haichang Biotech Co., Ltd.